PubRank

Yuankai Shi

Author PubWeight™ 29.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007 2.98
2 Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009 1.47
3 Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008 1.39
4 A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 2008 1.29
5 FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005 1.19
6 Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2006 1.16
7 DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res 2013 1.11
8 Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer 2011 1.10
9 Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013 0.99
10 Immunophenotypic study of basophils by multiparameter flow cytometry. Arch Pathol Lab Med 2008 0.96
11 Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009 0.93
12 Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J Med Genet 2010 0.93
13 Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011 0.93
14 Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark 2013 0.86
15 [Chinese guidelines on the diagnosis and treatment of primary lung cancer 
(2011 version)]. Zhongguo Fei Ai Za Zhi 2012 0.86
16 Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs 2011 0.86
17 Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. J Clin Apher 2012 0.82
18 A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections. Anticancer Drugs 2014 0.81
19 Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers. Anal Bioanal Chem 2015 0.80
20 Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leuk Res 2012 0.79
21 Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol 2015 0.78
22 Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant. Leuk Lymphoma 2014 0.78
23 [Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011 0.78
24 [Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib 
in Patients with Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2011 0.78
25 [Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. Zhongguo Fei Ai Za Zhi 2012 0.77
26 Biological markers: Tailoring treatment and trials to prognosis. Nat Rev Clin Oncol 2013 0.77
27 Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese population. Carcinogenesis 2013 0.77
28 [A standard protocol for detection of EGFR mutations in cytologic specimens]. Zhonghua Zhong Liu Za Zhi 2014 0.77
29 Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol 2013 0.76
30 A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma. Leuk Lymphoma 2015 0.76
31 Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer Chemother Pharmacol 2014 0.75
32 Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Biomed Pharmacother 2013 0.75
33 [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens]. Zhonghua Zhong Liu Za Zhi 2015 0.75
34 [Treatment choice for advanced non-small cell lung cancer patients who had gradual progression after EGFR-TKIs: 32 cases report]. Zhongguo Fei Ai Za Zhi 2013 0.75
35 [Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2013 0.75
36 [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy]. Zhonghua Zhong Liu Za Zhi 2002 0.75
37 [Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2012 0.75
38 Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma. Anal Bioanal Chem 2014 0.75
39 [Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance]. Zhongguo Fei Ai Za Zhi 2013 0.75
40 [The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2008 0.75
41 Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. J Pharm Biomed Anal 2013 0.75
42 Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. Int J Hematol 2008 0.75
43 [Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors]. Zhonghua Zhong Liu Za Zhi 2016 0.75
44 [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients]. Zhonghua Yi Xue Za Zhi 2002 0.75
45 [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2013 0.75
46 [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2013 0.75
47 [Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment]. Zhongguo Fei Ai Za Zhi 2013 0.75
48 [Results of combined therapy for 1260 patients with small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 2002 0.75
49 Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2013 0.75
50 [Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma]. Zhonghua Yi Xue Za Zhi 2015 0.75